147 related articles for article (PubMed ID: 22023215)
1. Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease.
Reid E; Nooka A; Blackmon J; Lechowicz MJ
Curr Drug Deliv; 2012 Jan; 9(1):41-51. PubMed ID: 22023215
[TBL] [Abstract][Full Text] [Related]
2. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of multicentric Castleman's disease with bilateral orbital tumour using rituximab.
Ide M; Ogawa E; Kasagi K; Kawachi Y; Ogino T
Br J Haematol; 2003 Jun; 121(5):818-9. PubMed ID: 12780800
[No Abstract] [Full Text] [Related]
4. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.
Hoffmann C; Schmid H; Müller M; Teutsch C; van Lunzen J; Esser S; Wolf T; Wyen C; Sabranski M; Horst HA; Reuter S; Vogel M; Jäger H; Bogner J; Arasteh K
Blood; 2011 Sep; 118(13):3499-503. PubMed ID: 21778341
[TBL] [Abstract][Full Text] [Related]
5. [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].
Pastor MA; Vasco B; Mosquera JM; Debén G; Bautista P; Requena L
Actas Dermosifiliogr; 2006; 97(6):385-90. PubMed ID: 16956518
[TBL] [Abstract][Full Text] [Related]
6. Multicentric Castleman's disease in a Ghanaian adult.
Dei-Adomakoh YA; Segbefia C; Ekem I; Taylor A
Ghana Med J; 2013 Jun; 47(2):92-5. PubMed ID: 23966747
[TBL] [Abstract][Full Text] [Related]
7. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.
Gérard L; Michot JM; Burcheri S; Fieschi C; Longuet P; Delcey V; Meignin V; Agbalika F; Chevret S; Oksenhendler E; Galicier L
Blood; 2012 Mar; 119(10):2228-33. PubMed ID: 22223822
[TBL] [Abstract][Full Text] [Related]
8. Successfully treated multicentric Castleman's disease with renal thrombotic microangiopathy using rituximab and corticosteroid.
Lee JP; Kim DK; Oh DY; Paik JH; Moon KC; Kim S; Kim YS
Clin Nephrol; 2011 Feb; 75(2):165-70. PubMed ID: 21255547
[TBL] [Abstract][Full Text] [Related]
9. Castleman's disease: from basic mechanisms to molecular therapeutics.
El-Osta HE; Kurzrock R
Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
[TBL] [Abstract][Full Text] [Related]
10. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of iatrogenic multicentric Castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient.
Speicher DJ; Sehu MM; Mollee P; Shen L; Johnson NW; Faoagali JL
Am J Transplant; 2014 May; 14(5):1207-13. PubMed ID: 24674650
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multicentric Castleman’s disease in HIV-1 infected and uninfected patients: a systematic review.
Rokx C; Rijnders BJ; van Laar JA
Neth J Med; 2015 Jun; 73(5):202-10. PubMed ID: 26087799
[TBL] [Abstract][Full Text] [Related]
13. A new prognostic score for AIDS-related lymphomas in the rituximab-era.
Barta SK; Xue X; Wang D; Lee JY; Kaplan LD; Ribera JM; Oriol A; Spina M; Tirelli U; Boue F; Wilson WH; Wyen C; Dunleavy K; Noy A; Sparano JA
Haematologica; 2014 Nov; 99(11):1731-7. PubMed ID: 25150257
[TBL] [Abstract][Full Text] [Related]
14. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.
Cervera Grau JM; Galiana Esquerdo G; Llorca Ferrándiz C; Briceño García H; Díaz Castellano M; Férriz Moreno P
Clin Transl Oncol; 2006 Jul; 8(7):540-1. PubMed ID: 16870545
[TBL] [Abstract][Full Text] [Related]
15. Multicentric Castleman's disease as a cause for unclear febrile episodes in a 55-year-old HIV-infected man.
Lederer H; Achermann Y; Tinguely M; Stenner F; Fehr J
Infection; 2012 Apr; 40(2):203-5. PubMed ID: 21837451
[TBL] [Abstract][Full Text] [Related]
16. How I treat HIV-associated multicentric Castleman disease.
Bower M
Blood; 2010 Nov; 116(22):4415-21. PubMed ID: 20688959
[TBL] [Abstract][Full Text] [Related]
17. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
[TBL] [Abstract][Full Text] [Related]
18. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels.
Newsom-Davis T; Bower M; Wildfire A; Thirlwell C; Nelson M; Gazzard B; Stebbing J
Leuk Lymphoma; 2004 Sep; 45(9):1939-41. PubMed ID: 15223659
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.
Powles T; Stebbing J; Montoto S; Nelson M; Gazzard B; Orkin C; Webb A; Bower M
Blood; 2007 Dec; 110(12):4132-3. PubMed ID: 18024800
[No Abstract] [Full Text] [Related]
20. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
Wyen C; Jensen B; Hentrich M; Siehl J; Sabranski M; Esser S; Gillor D; Müller M; Van Lunzen J; Wolf T; Bogner JR; Wasmuth JC; Christ H; Fätkenheuer G; Hoffmann C
AIDS; 2012 Feb; 26(4):457-64. PubMed ID: 22112600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
